Hospira, Korea’s Celltrion Get EU Nod For First Monoclonal Antibody Biosimilar
This article was originally published in PharmAsia News
Executive Summary
EMA recommends approval for two brands of Celltrion’s infliximab, one to be marketed by Hospira, as Europe moves closer to its first MAb biosimilar. The product would take on J&J/Merck’s Remicade in an era of budgetary pressures, but also physician concerns about biosimilar safety.